Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001714899-22-000040
Filing Date
2022-02-15
Accepted
2022-02-15 18:55:23
Documents
2
Period of Report
2022-02-11

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_164496930840504.html 4  
1 FORM 4 wf-form4_164496930840504.xml 4 5030
2 POWER OF ATTORNEY FOR: /S/ TYLER NIELSEN, BY POWER OF ATTORNEY poa.htm EX-24 2179
  Complete submission text file 0001714899-22-000040.txt   8639
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Issuer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O DENALI THERAPEUTICS INC. 151 OYSTER POINT BLVD., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address
Schuth Alexander O. (Reporting) CIK: 0001724311 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38311 | Film No.: 22640803